Key facts
- BioCorteX’s last known valuation is $13.3M (Mar 2023).
- It has raised $5.2M; the latest was Later Stage VC in Jan 2025.
- Notable investors include Draper Associates, Sofinnova Partners, Hoxton Ventures, Grow London, Merck Digital Sciences Studio — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for BioCorteX
- ·The full record, as it builds
Funding rounds
No funding rounds for BioCorteX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioCorteX
Operator of a biotechnology company intended to deliver effective therapeutics and de-risk the pharma pipeline by leveraging the synergy between drugs and bacteria. The company uses deep technology to simulate how the colossal number of microbiota interact with a drug, de-risking preclinical studies and clinical trials, enabling medications, cosmetics, personal care, manufacturing, and agriculture sectors to provide patients with better therapies and treatments.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2021
- Employees
- 13
- Website
- biocortex.com/
- Ownership
- Privately Held (backing)
BioCorteX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioCorteX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioCorteX in its N-PORT filings yet. We sweep new filings monthly.